Prostatic artery embolization may be an effective treatment for benign prostatic hyperplasia for men who may not be able to undergo transurethral resection of the prostate.
Prostatic artery embolization may be an effective treatment for benign prostatic hyperplasia for men who may not be able to undergo transurethral resection of the prostate, said researchers at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, Calif.
The minimally invasive option to surgery provided good response in volume reduction in prostate size and decrease in urinary tract symptoms among the majority of men in this small study, said Francisco Cesar Carnevale, MD, PhD, professor and chief of interventional radiology at the Hospital das Clinicas Hospital of the Faculty of Medicine at the University of Sao Paulo in Brazil.
The researchers studied 11 men (average age 68.5 years) who suffered with acute urinary retention due to an enlarged prostate (ranging from 30 grams to 90 grams) and who had already received medical treatment. The men all had urethral catheters and were waiting for surgery.
The procedure was performed under local anesthetic, and MRI was used to study the exact anatomy of the patients’ prostate. A one-millimeter diameter microcatheter was introduced into the prostate arteries in order to perform the embolization, which used resin microspheres.
Follow-up ranged from 16 months to 45 months. At one year following treatment, all men reported overall clinical improvement in lower urinary tract symptoms. At final follow-up, there was an overall volume reduction of 30 percent in prostate size. All men also reported a high degree of satisfaction and increased quality of life.
“I saw firsthand how these men responded to treatment,” said Ziv J. Haskal, MD, FSIR, a professor of radiology and surgery at the University of Maryland School of Medicine and editor-in-chief of the Journal of Vascular and Interventional Radiology. Haskal was one of many SIR members to travel to Brazil to learn about the treatment. “With the possibility of faster recovery - on an outpatient basis - and with no bladder catheters, reduced symptoms, improved urination and fewer potential side effects, prostatic artery embolization could signal a bold new change in accepted prostate therapy.”
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.